CNS Involvement in a Patient with Chronic Myeloid Leukemia

Table 1

European Leukemia Network’ summary of the most appropriate alternative therapeutic options based on BCR-ABL KD mutation status [4].

T315I	Ponatinib
F317L/V/I/C, T315A	Nilotinib, bosutinib^#, or ponatinib
V299L	Nilotinib or ponatinib
Y253H, E255V/K, F359V/I/C	Dasatinib, bosutinib^#, or ponatinib

^#Limited in vivo data suggest resistance to bosutinib in vivo in patients with E255K and, to a reduced extent, the E255V mutation.